P Joly, B Horvath, Α Patsatsi, S Uzun, R Bech, S Beissert, R Bergman, P Bernard, L Borradori, M Caproni, F Caux, G Cianchini, M Daneshpazhooh, D De, M Dmochowski, K Drenovska, J Ehrchen, C Feliciani, M Goebeler, R Groves, C Guenther, S Hofmann, D Ioannides, C Kowalewski, R Ludwig, Y L Lim, B Marinovic, A V Marzano, J M Mascaró, D Mimouni, D F Murrell, C Pincelli, C P Squarcioni, M Sárdy, J Setterfield, E Sprecher, S Vassileva, K Wozniak, S Yayli, G Zambruno, D Zillikens, M Hertl, E Schmidt
BACKGROUND: Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, pemphigus was almost always fatal. Due to its rarity, only few randomized controlled therapeutic trials are available. Recently, rituximab has been approved as first-line treatment for moderate and severe pemphigus vulgaris in Europe and the United States. OBJECTIVES: The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology (EADV) has initiated a throughout update of the guideline for the management of patients with pemphigus...
September 2020: Journal of the European Academy of Dermatology and Venereology: JEADV